Receptor-interacting serine/threonine-protein kinase 2 (RIPK2) plays a vital role in the regulation of innate and adaptive immune responses [39, 40], and its high expression has been found to be closely associated with poor prognosis of human kidney renal clear cell carcinoma [41], gastric cancer [42], inflammatory breast cancer (IBC) [43], glioblastoma [44, 45], and so on, and is a potential therapeutic target for a variety of cancers. This evidence concerns the gene RIPK2 and inflammatory breast carcinoma.